COVID-19 vaccination in Kazakhstan

Last updated

COVID-19 vaccination in Kazakhstan
COVID-19 vaccination coverage in Kazakhstan by region.svg
Share of population in Kazakhstan that has received at least one dose of COVID-19 vaccine by region as of 29 July 2022
Date1 February 2021 (2021-02-01) – present
Location Kazakhstan
Cause COVID-19 pandemic in Kazakhstan

COVID-19 vaccination in Kazakhstan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.[ citation needed ]

Contents

Background

Shortly after the COVID-19 outbreak in Kazakhstan, Erlan Ramanqūlov, the Director General of the National Center for Biotechnology announced in April 2020 the stages on developing the COVID-19 vaccine, acknowledging that clinical trials usually take up to 10 years to develop and that all verified research process would be cut short due to intense situation in the country, making the vaccine against coronavirus be produced usually faster and forecasted that it would be available to the public within next year and a half. [1]

On 18 May 2020, the Ministry of Education and Science announced that the preclinical trials for the local COVID-19 vaccine had begun of which was developed by the employees of the Research Institute of Biological Safety Problems of the Science Committee (BQPĞZÏ) under the Ministry by the strain of the coronavirus isolated from patients and that the World Health Organization (WHO) had registered the vaccine development. [2] At the cabinet meeting, Education and Science Minister Ashat Aimagambetov announced that five COVID-19 vaccines were being developed and that the preclinical trials would be tested on animals until September 2020, when the clinical stages would begin for humans. [3] In August 2020, the National Center for Expertise of Medicines and Medical Devices reported that the QazCovid-in vaccine showed no dangers during preclinical study stage and ruled that the testing could advance further into clinical trials on humans. [4] Starting 1 September 2020, the BQPĞZI began recruiting volunteers for conducting clinical trials of QazCovid-in. [5] In December 2020, the Ministry of Healthcare approved the final phase III of clinical trials by the BQPĞZI for 3,000 volunteers, by which the institute reported 96% efficiency rate of QazCovid-in. [6]

Kazakhstan has created its own COVID-19 vaccination, QazCovid-in, developed by the Research Institute for Biological Safety Problems. [7] On 7 April 2021, the Healthcare Minister Alexey Tsoi announced that the Kazakh government had requested 4 million doses of Russia's Sputnik V vaccine, in addition to 2 million doses already received earlier in 2021, as part of an ongoing vaccination programme alongside QazCovid-in. [8]

In October 2021, the first Kazakh vaccine to protect cats from COVID-19, NARUVAX-C19, was unveiled at the Kazagro/Kazfarm-2021 international exhibition. [9]

Vaccine in order

VaccineApprovalDeployment
Sputnik V Green check.svg YesGreen check.svg Yes
QazCovid-in Green check.svg YesGreen check.svg Yes
Sinopharm BIBP [10] Green check.svg YesGreen check.svg Yes
Sinovac [11] Green check.svg YesGreen check.svg Yes
Sputnik Light [12] Green check.svg YesDark Red x.svg No
QazCoVac-PDark Red x.svg NoDark Red x.svg No

Vaccination rate by region

RegionVaccinated population (as of 29 July 2022) [13]
AmountPercentage
1st dose2nd doseBooster dose1st dose2nd doseBooster dose
Akmola Region 376,526363,78551.3%49.6%
Aktobe Region 442,646435,54148.6%47.8%
Almaty Region 1,183,8051,130,83455.9%53.4%
Atyrau Region 292,152276,46743.4%41.1%
East Kazakhstan Region 1,032,2151,025,71076.2%75.7%
Jambyl Region 772,156762,45367.0%66.1%
Karaganda Region 726,370678,60953.0%49.5%
Kostanay Region 380,772367,48344.5%42.9%
Kyzylorda Region 516,071510,59962.0%61.4%
Mangystau Region 279,861272,26137.3%36.3%
Pavlodar Region 385,060375,95451.6%50.4%
North Kazakhstan Region 342,656338,13364.1%63.3%
Turkistan Region 1,294,9821,290,14562.0%61.8%
West Kazakhstan Region 297,268287,56144.5%43.1%
Almaty 1,211,4791,186,64659.1%57.9%
Nur-Sultan 542,653516,13043.0%40.9%
Shymkent 707,126696,29862.9%61.9%
Flag of Kazakhstan.svg  Kazakhstan 10,783,79810,514,6095,012,63057.5%56.1%26.7%
Total doses:26,311,037

Related Research Articles

<span class="mw-page-title-main">Asqar Mamin</span> Prime Minister of Kazakhstan from 2019 to 2022

Asqar Uzaqbaiuly Mamin is a Kazakh politician and economist who served as the Prime Minister of Kazakhstan from 2019 to 2022, resigning due to pressure from the 2022 Kazakh unrest. He served as First Deputy Prime Minister from 9 September 2016 to 21 February 2019. Previously, he was the president of the Kazakhstan Temir Zholy, the national railway company of Kazakhstan. He also serves as the president of the Kazakhstan Ice Hockey Federation, a position he assumed in 2008.

The COVID-19 pandemic in Belarus was a part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Belarus, when the first case of COVID-19 in the country was registered in Minsk on 28 February 2020. As of 29 January 2023, a total of 19,047,714 vaccine doses have been administered.

<span class="mw-page-title-main">COVID-19 vaccine</span> Vaccine against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

The COVID-19 pandemic in Kazakhstan was a part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have reached Kazakhstan on 13 March 2020 after two Kazakh citizens in Almaty returned from Germany. That same day, two more cases were confirmed, with one female arriving from Italy in Astana and the other from Germany in Almaty as well. Following the outbreak, on 15 March 2020, President Kassym-Jomart Tokayev declared a state of emergency that was set to last until 15 April 2020. However, measures were prolonged in order to curb the transmission of the virus, leading to many notable holidays such as Nowruz and the Victory Day being cancelled. On 19 March 2020, a strict quarantine was placed on the cities of Astana and Almaty, where the most cases were occurring. On 30 March 2020, Atyrau and five cities in Karaganda Region went under a lockdown.

Turkmenistan is the only remaining sovereign country in the world that has not reported any cases of COVID-19. There were no confirmed cases of COVID-19 in Turkmenistan, with the totalitarian government being proactive in censoring relevant information. It is however suspected to have spread in the country unreported; specifics are difficult to ascertain and confirm in absence of independent media.

<span class="mw-page-title-main">Eljan Birtanov</span> Kazakh politician

Yelzhan Amantaiuly Birtanov is a Kazakh politician who served as the Minister of Healthcare from 2017 to 2020.

<span class="mw-page-title-main">Sputnik V COVID-19 vaccine</span> Russian vaccine against COVID-19

Sputnik V or Gam-COVID-Vac is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.

<span class="mw-page-title-main">CoronaVac</span> Vaccine against COVID-19

CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen, and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), the temperatures at which flu vaccines are kept.

<span class="mw-page-title-main">COVID-19 vaccination in India</span> Immunisation programme against COVID-19 in India

India began administration of COVID-19 vaccines on 16 January 2021. As of 4 March 2023, India has administered over 2.2 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines. In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">EpiVacCorona</span> EpiVacCorona vaccine against COVID-19

EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the Russian VECTOR Center of Virology. The lack of protective effectiveness of EpiVacCorona, which is still in use in Russia, has been reported in scientific literature and in the media. The vaccine consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. A phase III clinical trial to show whether or not the vaccine can protect people against COVID-19 was launched in November 2020 with more than three thousand participants. The conclusions and results of the trial have not been made public.

<span class="mw-page-title-main">COVID-19 vaccination in Russia</span> Plan to immunize against COVID-19

The COVID-19 vaccination campaign in Russia is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Russia became the first country to begin a mass COVID-19 vaccination programme on 5 December 2020, starting with primarily doctors, medical workers and teachers. In January 2021, this was extended to the entire population.

CoviVac is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre, which is an institute of the Russian Academy of Sciences. It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia. It obtained a permission for phase III clinical trial on 2 June 2021.

<span class="mw-page-title-main">QazCovid-in</span> Vaccine candidate against COVID-19

QazCovid-in, commercially known as QazVac, is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.

<span class="mw-page-title-main">COVID-19 vaccination in South Korea</span> Plan to immunize against COVID-19

COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

<span class="mw-page-title-main">Sputnik Light</span> Vaccine against COVID-19

Sputnik Light is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). The institute says this version would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly. It will also be used as a third (booster) dose for those who received Sputnik V at least 6 months earlier.

<span class="mw-page-title-main">COVID-19 vaccine clinical research</span> Clinical research to establish the characteristics of COVID-19 vaccines

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

Kunsulu Daltonqyzy Zakaryia is a Kazakh researcher in biological safety, Doctor of Biological Sciences, and from April 2023 the President of the Kazakh Academy of Sciences.

References

  1. "Названы сроки создания вакцины против COVID-19 в Казахстане - Новости Казахстана и мира на сегодня". 24.kz (in Russian). April 17, 2020. Archived from the original on July 15, 2021. Retrieved July 15, 2021.
  2. "В Казахстане начали доклинические испытания вакцины от коронавируса - Аналитический интернет-журнал Vласть". vlast.kz (in Russian). May 18, 2020. Archived from the original on May 26, 2020. Retrieved July 15, 2021.
  3. Дубовая, Мария (June 19, 2020). "Испытания казахстанской вакцины против коронавируса на людях планируют начать в сентябре". informburo.kz (in Russian). Archived from the original on July 24, 2020. Retrieved July 15, 2021.
  4. "Казахстанская вакцина от COVID-19 может быть применена на людях-добровольцах – НЦЭЛС". KazTAG (in Russian). August 19, 2020. Archived from the original on July 14, 2023. Retrieved July 14, 2023.
  5. "THE RECEPTION OF QUESTIONNAIRES OF VOLUNTEERS TO PARTICIPATE IN CLINICAL TRIALS OF THE KAZAKHSTANI QAZCOVID-IN®-COVID-19 INACTIVATED VACCINE, DEVELOPED AT RIBSP HAS BEGUN" (Press release). Research Institute for Biological Safety Problems. September 1, 2020. Archived from the original on July 14, 2023. Retrieved July 14, 2023.
  6. "Kazakhstan starts vaccination of three thousand volunteers with domestic QazCovid-in vaccine". primeminister.kz. December 19, 2020. Archived from the original on July 14, 2023. Retrieved July 14, 2023.
  7. Yergaliyeva, Aidana (December 20, 2020). "Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in". The Astana Times. Archived from the original on December 28, 2020. Retrieved April 7, 2021.
  8. "Kazakhstan asks Russia for additional Sputnik V supplies". Reuters. April 7, 2021. Archived from the original on May 11, 2021. Retrieved April 7, 2021.
  9. October 2021, Saniya Bulatkulova in Society on 25 (October 25, 2021). "No Pet Left Behind! New NARUVAX-C19 Vaccine for Cats Unveiled in Nur-Sultan". The Astana Times. Archived from the original on December 8, 2021. Retrieved December 8, 2021.{{cite web}}: CS1 maint: numeric names: authors list (link)
  10. Satubaldina, Assel (April 30, 2021). "Three Vaccines to Become Available to Kazakh Citizens". The Astana Times. Archived from the original on April 30, 2021. Retrieved May 1, 2021.
  11. "В Казахстан доставили первую партию китайской вакцины CoronaVac | Kazakhstan Today". www.kt.kz (in Russian). Archived from the original on June 7, 2021. Retrieved June 7, 2021.
  12. "Kazakhstan approves Russia's single-dose Sputnik Light vaccine". Reuters. Moscow. July 15, 2021. Archived from the original on July 15, 2021. Retrieved July 15, 2021.
  13. "Информация о проведении вакцинации населения против КВИ на 29.07.2022 г. в разрезе регионов". gurk.kz (in Russian). МЕДИА-ЦЕНТР МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РК. July 29, 2022. Archived from the original on July 30, 2022. Retrieved July 30, 2022.